相关产品推荐更多 >

抗人ITGB7单克隆抗体 | Anti-Human ITGB7 Monoclonal Antibody
询价
抗CD74单抗 | Anti-CD74 Monoclonal Antibody, NBAB-188796
询价
抗Influenza A H7N7 (A/Netherlands/219/2003) Hemagglutinin / HA | Influenza A H7N7 (A/Netherlands/219/2003) Hemagglutinin / HA
询价
抗FLI1抗体 | Anti-FLI1 Polyclonal Antibody, NBAB-110448
询价
抗鼠MLC1抗体 | Anti-MLC1 Polyclonal Antibody
询价
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 免疫原:
A synthetic peptide corresponding to the center region of the Human CCR2/CD192
- 形态:
liquid
- 保存条件:
见COA
- 克隆性:
单克隆
- 保质期:
见COA
- 库存:
大量
- 供应商:
北京辰辉创聚生物技术有限公司
- 应用范围:
FCM
- 抗体英文名:
Anti-CCR2 Monoclonal Antibody (APC)
- 抗体名:
抗CCR2 (APC)单抗
- 规格:
100ul; 500ul; 1ml

| 产品信息
品名:NebuSelect™ Anti-CCR2 Monoclonal Antibody (APC)
货号:NBAB-101858
品牌:辰辉创聚生物®️
规格:100ul; 500ul; 1ml
| 产品描述
NebuSelect™ Anti-CCR2 Monoclonal Antibody (APC) (CAT# NBAB-101858) was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with a synthetic peptide corresponding to the center region of the Human CCR2/CD192, and it was conjugated with APC under optimum conditions, the unreacted APC was removed.
| 产品属性
Product Category:Mouse MAb
Reactivity:Human
Specificity:Human CCR2
Immunogen:A synthetic peptide corresponding to the center region of the Human CCR2/CD192
Isotype:Monoclonal Mouse IgG1
Purification:Protein A
Buffer:0.2 μm filtered solution in PBS with 0.5% BSA and 0.09% sodium azide
Conjugate:APC
Applications:FCM
Dilution:
Storage:This liquid antibody can be stored at 2℃-8℃ for at least two weeks. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20℃. When reconstituted in sterile pH 7.4 0.01M PBS or antibody diluent, the antibody is stable for at least two weeks at 2-4℃.
For Research Use Only!
To get more information, please contact us freely.
郑重声明:仅用于科学研究,不可用于诊断或治疗。
更多产品细节,请联系我司相关客服人员。
风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验「神药」再显威!杨黄浩等让二甲双胍扮演 PD-L1 「单抗」角色,提高治疗效果
ICBs 的抗肿瘤效果。 该研究成果以 Reducing PD-L1 expression with a self-assembled nanodrug: an alternative to PD-L1 antibody for enhanced chemo-immunotherapy. 为题,发表在了 2021 年 1 月 1 日的 Theranostics 上 [1]。 图片来源:Theranostics 研究内容:此前有研究报道,二甲双胍可以抑制肿瘤进展,改善癌症患者的预后和生存率。此外,也有研
Conjugation of monoclonal antibodies
Conjugation of monoclonal antibodies Prelude: You are free to copy and distribute these documents at will--but please do so in their entirety
医学生理病理与临床分册2000,20(2):137-140.[5]Yang XD,Jia XC,Corvalan JR, etal.Development of ABX-EGF,a fully human anti-EGF receptor monoclonal antibody,forcancertherapy.Hematology, 2001,38:17-13.[6]Herbst RS,langer CJ.Epidermal growth factor receptors as a target
技术资料暂无技术资料 索取技术资料





